AI Proteins Raises $41.5M Series A to Accelerate AI-Designed De Novo Miniprotein Therapeutics

AI Proteins, a Boston-based biotech startup, has closed $41.5 million in Series A financing led by Mission BioCapital and Santé Ventures, with participation from Lightchain Capital, Cobro Ventures, and others1 2 4 6 7 8.

The funding will accelerate the development of AI-driven design and engineering of de novo miniproteins—proteins built from scratch using artificial intelligence, unconstrained by natural evolution or human bias2 4 6.

AI Proteins' proprietary platform leverages generative AI, synthetic biology, and robotics to create modular miniproteins optimized for diverse therapeutic mechanisms, such as targeted delivery and multispecific agents2 4 6.

The company has announced the adoption of a hub-and-spoke business model, allowing its core technology platform to scale while spinning out specialized programs as subsidiaries2.

AI Proteins partners with major biopharmaceutical companies while progressing its own internal therapeutic pipeline, aiming to advance lead candidates into IND-enabling studies2 4.

Beyond therapeutics, potential applications of AI Proteins' technology include diagnostics, agricultural products, and research reagents where de novo miniproteins could surpass natural proteins in performance2.

The Series A investment marks a pivotal inflection point for AI Proteins, providing substantial resources to industrialize the design-build-test cycle for miniprotein development and improve their AI models through accumulation of large datasets2 4 6.